Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577549 | 1.00 | PDGFRB (0.38) | PDGFRBEGFRKDRABCG2MAPT | |
| SCHEMBL23576717 | 0.92 | PDGFRB (0.38) | PDGFRBEGFRKDRABCG2MAPT | |
| SCHEMBL29909762 | 0.92 | PDGFRB (0.38) | PDGFRBEGFRKDRABCG2MAPT | |
| SCHEMBL29909063 | 0.89 | ABCG2 (0.46) | ABCG2MAPTKDM4E | |
| SCHEMBL23601280 | 0.89 | ABCG2 (0.46) | ABCG2MAPTKDM4E | |
| SCHEMBL23601024 | 0.88 | ABCG2 (0.38) | PDGFRBEGFRKDRABCG2MAPT | |
| SCHEMBL23577209 | 0.87 | ABCG2 (0.38) | ABCG2MAPT | |
| SCHEMBL23601325 | 0.87 | PDGFRB (0.40) | PDGFRBEGFRKDRMAPTGABRA1 | |
| SCHEMBL23576902 | 0.86 | PDGFRB (0.35) | PDGFRBEGFRKDR | |
| SCHEMBL23576900 | 0.86 | PDGFRB (0.35) | PDGFRBEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | PDGFRB 1157/4885EGFR 1239/4885KDR 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.